Latest in Bone & Joint Health

Making bone health supplements palatable

Martin Koeberle and Verena Garsuch of HERMES PHARMA explore the challenges associated with bringing more convenient combined calcium/vitamin D3 bone health supplements to market and looks at how the application of specific formulation expertise and know-how can help

Find out more

You need to be a subscriber to read this article.
Click here to find out more.

Industrial data mastery: navigating the 2025 landscape

As industrial manufacturers contend with the ever-increasing volume and variety of operational data, the year ahead promises both complexity and opportunity
See more

Rousselot reveals Peptan collagen peptides and bone study results

A new study led by Rousselot and INRA presents scientific evidence that Peptan collagen peptides improve overall bone health by simultaneously targeting bone formation and bone resorption

Omya launches new Calcipur DC range

Calcipur DC can be used as an active ingredient in nutraceuticals and as a diluent in pharmaceuticals

Rousselot brings new perspectives for pharma and nutra applications

Leading global producer of gelatin and collagen peptides, Rousselot, has announced that it will reveal two new products at its 2018 Innovation Days

Helsinn Investment Fund leads financial round in GreenBone

New fund backed by the Helsinn Group, focused on supporting early stage opportunities in areas of high unmet patient need

Novel Nanobody to begin clinical development in osteoarthritis

Ablynx to receive €15m milestone payment from Merck

Pharnext begins partnership with Tasly, Chinese pharma group

Partnership will exploit the potential of modernised Chinese traditional medicine to make new drug combinations

Sanofi and Regeneron receive CHMP positive opinion for Kevzara

Kevzara (sarilumab) can be used to treat adult patients with moderately to severely active rheumatoid arthritis

The new F-Gas Regulation and its impact on pharmaceutical freeze-drying

Freeze-drying or lyophilization represents a pivotal process in the life sciences industry. During the past five decades, the technology involved has evolved into a complex, integrated system that balances both technical and biological specifications with economic, safety, and environmental concerns

Latest posts in Bone & Joint Health

Collaboration to identify relapse triggers of Rheumatoid Arthritis

Oxford BioDynamics collaboration to identify biological factors that trigger disease relapses in Rheumatoid Arthritis

Rheumatoid arthritis market to hit $28.5bn by 2025

The rheumatoid arthritis space across 8MM will grow from $19.5bn in 2015, representing a compound annual growth rate of 3.9%, according to GlobalData

Unmet needs in rheumatoid arthritis treatment could be addressed by first-in-class pipeline

RA remains an incurable condition with no therapeutics that directly act to restore bone content

Osteoporosis – romosozumab

Osteoporosis occurs when the rate at which new bone is being made is slower than the rate at which it is lost, with the bones becoming more prone to fracture

Amgen and Astellas agree alliance in Japan

Will focus on co-development of five Amgen medicines in Japan

Gout – pegloticase

Drugs such as allopurinol and probenecid can be used to reduce uric acid levels, but do not work in all patients

Japanese regulator approves osteoporosis jelly

Teijin Pharma plans to launch first oral jelly for osteoporosis later this year

Fujifilm Kyowa Kirin Biologics starts operations

The jv between Fujifilm and Kyowa Hakko Kirin will develop, manufacture and sell biosimilars

OctoPlus signs agreement with pharma company to develop controlled release formulation

Of a therapeutic compound for local delivery into joints

Stellar to acquire Tribute Pharmaceuticals

Tribute founder Rob Harris to lead merged firm